表紙
市場調査レポート

La Jolla Pharmaceutical Company:製品パイプライン分析

La Jolla Pharmaceutical Company - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 293914
出版日 ページ情報 英文 39 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
La Jolla Pharmaceutical Company:製品パイプライン分析 La Jolla Pharmaceutical Company - Product Pipeline Review - 2016
出版日: 2016年06月22日 ページ情報: 英文 39 Pages
概要

当レポートでは、La Jolla Pharmaceutical Companyにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

La Jolla Pharmaceutical Companyの基本情報

  • La Jolla Pharmaceutical Companyの概要
  • 主要情報
  • 企業情報

La Jolla Pharmaceutical Company:R&Dの概要

  • 主な治療範囲

La Jolla Pharmaceutical Company:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

La Jolla Pharmaceutical Company:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

La Jolla Pharmaceutical Company:薬剤プロファイル

  • LJPC-501
  • LJPC-0712
  • LJPC-101
  • LJPC-201
  • LJPC-30Sa
  • LJPC-30Sb
  • LJPC-401
  • LJPC-6417
  • LJPC-301

La Jolla Pharmaceutical Company:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

La Jolla Pharmaceutical Company:最近のパイプライン動向

La Jolla Pharmaceutical Company:休止中のプロジェクト

La Jolla Pharmaceutical Company:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • GCS-100
    • LJPC-1010

La Jolla Pharmaceutical Company:企業発表

La Jolla Pharmaceutical Company:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08071CDB

Summary

Global Markets Direct's, 'La Jolla Pharmaceutical Company - Product Pipeline Review - 2016', provides an overview of the La Jolla Pharmaceutical Company's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by La Jolla Pharmaceutical Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of La Jolla Pharmaceutical Company
  • The report provides overview of La Jolla Pharmaceutical Company including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses La Jolla Pharmaceutical Company's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features La Jolla Pharmaceutical Company's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate La Jolla Pharmaceutical Company's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for La Jolla Pharmaceutical Company
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding La Jolla Pharmaceutical Company's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • La Jolla Pharmaceutical Company Snapshot
    • La Jolla Pharmaceutical Company Overview
    • Key Information
    • Key Facts
  • La Jolla Pharmaceutical Company - Research and Development Overview
    • Key Therapeutic Areas
  • La Jolla Pharmaceutical Company - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • La Jolla Pharmaceutical Company - Pipeline Products Glance
    • La Jolla Pharmaceutical Company - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • La Jolla Pharmaceutical Company - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • La Jolla Pharmaceutical Company - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • La Jolla Pharmaceutical Company - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • La Jolla Pharmaceutical Company - Drug Profiles
    • LJPC-501
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LJPC-401
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LJPC-0712
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LJPC-30Sa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LJPC-30Sb
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LJPC-6417
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Undisclosed Indications
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • La Jolla Pharmaceutical Company - Pipeline Analysis
    • La Jolla Pharmaceutical Company - Pipeline Products by Target
    • La Jolla Pharmaceutical Company - Pipeline Products by Route of Administration
    • La Jolla Pharmaceutical Company - Pipeline Products by Molecule Type
    • La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action
  • La Jolla Pharmaceutical Company - Recent Pipeline Updates
  • La Jolla Pharmaceutical Company - Dormant Projects
  • La Jolla Pharmaceutical Company - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • GCS-100
      • LJPC-1010
  • La Jolla Pharmaceutical Company - Company Statement
  • La Jolla Pharmaceutical Company - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • La Jolla Pharmaceutical Company, Key Information
  • La Jolla Pharmaceutical Company, Key Facts
  • La Jolla Pharmaceutical Company - Pipeline by Indication, 2016
  • La Jolla Pharmaceutical Company - Pipeline by Stage of Development, 2016
  • La Jolla Pharmaceutical Company - Monotherapy Products in Pipeline, 2016
  • La Jolla Pharmaceutical Company - Phase III, 2016
  • La Jolla Pharmaceutical Company - Phase I, 2016
  • La Jolla Pharmaceutical Company - Preclinical, 2016
  • La Jolla Pharmaceutical Company - Discovery, 2016
  • La Jolla Pharmaceutical Company - Unknown, 2016
  • La Jolla Pharmaceutical Company - Pipeline by Target, 2016
  • La Jolla Pharmaceutical Company - Pipeline by Route of Administration, 2016
  • La Jolla Pharmaceutical Company - Pipeline by Molecule Type, 2016
  • La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action, 2016
  • La Jolla Pharmaceutical Company - Recent Pipeline Updates, 2016
  • La Jolla Pharmaceutical Company - Dormant Developmental Projects,2016
  • La Jolla Pharmaceutical Company - Discontinued Pipeline Products, 2016
  • La Jolla Pharmaceutical Company, Subsidiaries

List of Figures

  • La Jolla Pharmaceutical Company - Pipeline by Top 10 Indication, 2016
  • La Jolla Pharmaceutical Company - Pipeline by Stage of Development, 2016
  • La Jolla Pharmaceutical Company - Monotherapy Products in Pipeline, 2016
  • La Jolla Pharmaceutical Company - Pipeline by Target, 2016
  • La Jolla Pharmaceutical Company - Pipeline by Route of Administration, 2016
  • La Jolla Pharmaceutical Company - Pipeline by Molecule Type, 2016
  • La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action, 2016
Back to Top